Halminen Olli, Tenhunen Henni, Heliste Antti, Seppälä Timo
Department of Industrial Engineering and Management, Aalto University, Espoo, Finland.
Research Institute of the Finnish Economy, ETLA, Helsinki, Finland.
Stud Health Technol Inform. 2019 Jul 4;262:268-271. doi: 10.3233/SHTI190070.
Venture Capital (VC) funding raised by companies producing Artificial Intelligence (AI) or Machine Learning (ML) solutions is on the rise and a driver of technology development. In healthcare, VC funding is distributed unevenly and certain technologies have attracted significantly more funding than others have. We analyzed a database of 106 Healthcare AI companies collected from open online sources to understand factors affecting the VC funding of AI companies operating in different areas of healthcare. The results suggest that there is a significant connection between higher funding and having research organizations or pharmaceutical companies as the customer of the product or service. In addition, focusing on AI solutions that are applied to direct patient care delivery is associated with lower funding. We discuss the implications of our findings for public health technology funding institutions.
生产人工智能（AI）或机器学习（ML）解决方案的公司筹集的风险投资（VC）正在增加，并且是技术发展的驱动力。在医疗保健领域，风险投资的分布不均衡，某些技术吸引的资金明显多于其他技术。我们分析了从公开在线来源收集的106家医疗保健人工智能公司的数据库，以了解影响在医疗保健不同领域运营的人工智能公司获得风险投资的因素。结果表明，获得更多资金与拥有研究机构或制药公司作为产品或服务的客户之间存在显著关联。此外，专注于应用于直接患者护理的人工智能解决方案与获得较少资金有关。我们讨论了我们的研究结果对公共卫生技术资助机构的影响。
